Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Neutropenia 3Febrile Neutropenia 3Small Cell Lung Carcinoma 1Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Malignant Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chemotherapy-induced Neutropenia 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 4Injections 2toripalimab 1penpulimab 1pegylated granulocyte colony-stimulating factor 1irinotecan sucrosofate 1fluzoparib 1cabiralizumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1IMM-101 1Fluorouracil 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Pancreatic Cancer × pegylated granulocyte colony-stimulating factor × Clear all
NCT04239001 2020-01-23

Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase NA Unknown
20 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡